The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal malignancies. Cancer stem cells (CSCs), which are not targeted by current therapies, may be the reason for pronounced therapy resistance. A new treatment option in phase II trials is cabozantinib that inhibits the pancreatic CSC surfac...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Hage, C, Rausch, V, Giese, N, Giese, T, Schönsiegel, F, Labsch, S, Nwaeburu, C, Mattern, J, Gladkich, J, Herr, I
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Nature Publishing Group 2013
विषय:
Original Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3674365/
https://ncbi.nlm.nih.gov/pubmed/23661005
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddis.2013.158
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन